EGFRvIII Is Expressed in Cellular Areas of Tumor in a Subset of Glioblastoma

Access this Article

Author(s)

    • NOZAWA Takanori
    • Department of Neurosurgery, Brain Research Institute, University of Niigata|Department of Pathology, Brain Research Institute, University of Niigata
    • FUJII Yukihiko
    • Department of Neurosurgery, Brain Research Institute, University of Niigata
    • KAKITA Akiyoshi
    • Department of Pathology, Brain Research Institute, University of Niigata
    • OKADA Masayasu
    • Department of Neurosurgery, Brain Research Institute, University of Niigata
    • NATSUMEDA Manabu
    • Department of Neurosurgery, Brain Research Institute, University of Niigata
    • EDA Takeyoshi
    • Department of Neurosurgery, Brain Research Institute, University of Niigata
    • ABE Hideaki
    • Department of Neurosurgery, Brain Research Institute, University of Niigata
    • OISHI Makoto
    • Department of Neurosurgery, Brain Research Institute, University of Niigata

Abstract

<p>Epidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific cell surface antigen often expressed in glioblastoma and has drawn much attention as a possible therapeutic target. We performed immunohistochemistry on histology sections of surgical specimens taken from 67 cases with glioblastoma, isocitrate dehydrogenase-wild type, and evaluated the morphological characteristics and distribution of the EGFRvIII-positive tumor cells. We then evaluated the localization of EGFRvIII-expression within the tumor and peritumoral areas. EGFRvIII immunopositivity was detected in 15 specimens taken from 13 patients, including two recurrent specimens taken from the same patient at relapse. Immunofluorescence staining demonstrated that EGFRvIII-positive cells were present in cells positive for glial fibrillary acidic protein (GFAP), and some showed astrocytic differentiation with multiple fine processes and others did not shown. The EGFRvIII-positive cells were located in cellular areas of the tumor, but not in the invading zone. In the two recurrent cases, EGFRvIII-positive cells were markedly decreased in one case and retained in the other. With regard to overall survival, univariate analysis indicated that EGFRvIII-expression in patients with glioblastoma was not significantly associated with a favorable outcome. Double-labeling immunofluorescence staining of EGFRvIII and GFAP showed that processes of large, well differentiated, GFAP-positive glia extend to and surround less differentiated, EGFRvIII-positive glial cells in cellular areas of tumor. However, in the tumor periphery, EGFRvIII-positive tumor cells were not observed. This finding suggests that EGFRvIII is involved in tumor proliferation, but that invading glioma cells lose their EGFRvIII expression.</p>

Journal

  • Neurologia medico-chirurgica

    Neurologia medico-chirurgica 59(3), 89-97, 2019

    The Japan Neurosurgical Society

Codes

Page Top